Early-phase studies show therapeutic potential of oncolytic viruses across cancer types
However, presented findings raise some questions about their efficacy in non-injected lesions and the durability of responses
Pre-operative immunoradiation shows clinical benefit in patients with high-risk, early-stage breast cancer
Results from the Neo-CheckRay study report an acceptable toxicity profile with the addition of a PD-L1 inhibitor to neoadjuvant chemotherapy and stereotactic body radiation therapy
Early-stage immunotherapy significantly prolongs overall survival in triple-negative breast cancer
Final results from the KEYNOTE-522 study confirm that the integration of pembrolizumab into the treatment regimen has the potential to transform patient management, but careful patient selection and monitoring for toxicities will be crucial
Clinical activity reported for novel first-line combination strategies in advanced triple-negative breast cancer
Early-phase clinical trial results show promise to optimise the current standard of care by using dual-targeting agents and investigating the most effective chemotherapy backbone for PD-L1 blockade
Intravesical system for prolonged delivery of gemcitabine improves outcomes in two forms of bladder cancer
Findings from two studies show high rates of complete remissions in patients with Bacillus Calmette-Guérin unresponsive high-risk non-muscle-invasive bladder cancer and muscle-invasive bladder cancer
Adding durvalumab to neoadjuvant chemotherapy improves survival in muscle-invasive bladder cancer
Practice changing results of event-free survival and overall survival are reported from the NIAGARA study
Multi-cancer early detection – promise or reality?
While there has been significant progress in the development of these blood tests, hurdles remain including test sensitivity and false positives
Claudin-targeted antibody–drug conjugates are promising treatments for solid tumours
According to results from several phase I trials, this precision oncology strategy also offers manageable safety
Mixed results reported for cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer
Final overall survival data from the CONTACT-02 study are negative, but a survival advantage was observed with the novel combination in patients with liver or bone metastasis
Questions still remain on optimal adjuvant therapy in advanced melanoma
Overall survival benefits of systemic therapy in the adjuvant setting are still unclear in clinical trials, and may need to be complemented with real-world studies